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PENJELASAN INTERLEUKIN-17A DALAM 
PENGAWALATURAN PEMBEZAAN OSTEOGENIK SEL STEM 
DARIPADA GIGI SUSU MANUSIA YANG TERLUPAS  
ABSTRAK 
Sehingga kini, data   yang   menunjukkan   penglibatan   IL-17A   di   dalam   
pembentukan semula tulang amat terhad. Pengaktif reseptor ligand NF-κB (RANKL) 
telah menunjukkan peningkatan dalam penyerapan tulang manakala osteoprotegerin 
(OPG) pula menyokong osteogenesis. Oleh itu, tujuan kajian ini dilakukan adalah 
untuk mengenal pasti potensi peranan IL-17A dalam mengawal selia proliferasi, 
pembezaan osteogenik dan sistem OPG / RANKL sel-sel stem dari gigi susu manusia 
yang terlupas (SHED). SHED telah dikultur di dalam dua  keadaan yang berbeza; di 
dalam media alfa minimum essential (α-MEM) dan di dalam α- MEM yang ditambah 
dengan reagen osteogenik (OM). Kedua-dua kumpulan ini dirawat dengan kepekatan 
rIL-17A yang berbeza seperti 5, 10, 25, 50 dan 100ng/ml. Sel yang dirawat kemudian 
dianalisa untuk aktiviti proliferasi menggunakan asai MTS dan aktiviti pembezaan   
menggunakan asai alkalin fosfatase, aktiviti mineralisasi menggunakan Alizarin 
merah dan Von Kossa dan ekspresi penanda tulang dan sel stem serta apoptosis  
menggunakan   analisis ‘flow  cytometry’. Potensi pembezaan osteogenik seterusnya 
dinilai dengan mengukur penanda osteogenik yang terpilih seperti ALP,COL1A1,   
RUNX2, OCN, OPN, OPG, and RANKL menggunakan ‘real time PCR’ dan 
‘Western blot’. Penglibatan laluan pengisyaratan MAPK dan miRNA-145 dalam 
mekanisme pembezaan osteogenik oleh SHED yang dirawat dengan rIL-17A turut 
dinilai dalam kajian ini. Rawatan rIL-17A ke atas SHED dan SHED+OM   
menyebabkan peningkatan proliferasi dan aktiviti ALP yang dipengaruhi oleh dos 
yang digunakan. Samajuga, pewarnaan Alizarin merah dan Von Kossa   
 xxi 
 
menunjukkan peningkatan  aktiviti mineralisasi oleh  rawatan rIL-17A di dalam   
kedua-dua sel SHED  dan  SHED+OM Menariknya, sel-sel  yang  dirawat  dengan  
rIL-17A  menunjukkan penurunan penanda  sel  stem  (c-Myc dan Nanog) secara  
beransur-ansur di dalam kedua-dua sel sementara peningkatan ekspresi penanda 
osteogenik (ALP dan COL1A1) telah dibuktikan seiring dengan masa. SHED yang 
dirawat dengan rIL-17A juga berkemampuan untuk membantutkan apoptosis dalam 
kedua-dua kumpulan. Tambahan lagi ekspresi ALP, COL1A1, RUNX2, OCN, OPN 
dan OPG telah dikawalnaik dengan signifikannya di dalam SHED yang dirawat   
dengan rIL-17A dalam kedua-dua kumpulan. Walau bagaimanapun, ekspresi 
RANKL telah dikawalturun. Yang menariknya lagi, nisbah OPG/RANKL telah 
meningkat dengan signifikan dalam kumpulan yang dirawat dengan rIL-17A. Kami 
juga telah menunjukkan laluan pengisyaratan MAPK yang diaktifkan oleh IL-17A 
melalui kawalnaik yang signifikan semua pengaktif huluan dan sasaran hiliran ERK, 
P38 dan laluan JNK. Sebagai tambahan, SHED yang dirawat dengan rIL17A turut 
menunjukkan peningkatan dalam ekspresi miR-145. Buat pertama kalinya, 
penemuan ini menunjukkan rIL-17A menggalakkan   proliferasi dan meningkatkan 
osteogenesis dengan menggalakkan pembezaan osteogenik dengan mengubah laluan 
isyarat OPG/RANKL dan meningkatkan aktiviti mineralisasi. Kajian ini juga 
menunjukkan kemungkinan peranan laluan pengisyaratan MAPK dan miR-145 
dalam pembezaan osteogenik oleh SHED yang diaruh oleh IL-17A. Penemuan ini 
sekaligus mencadangkan peranan penting IL-17A dalam mekanisme pembentukan 
semula tulang. 
  
 xxii 
 
 ELUCIDATION OF INTERLEUKIN-17A IN REGULATING 
OSTEOGENIC DIFFERENTIATION OF STEM CELLS FROM 
HUMAN EXFOLIATED DECIDUOUS TEETH 
ABSTRACT 
To date, limited studies describe the involvement of interleukin-17A(IL-17A) 
in bone remodelling. Receptor activator of NF-κB ligand (RANKL) has been 
shown to augment bone resorption whereas osteoprotegerin (OPG) favours 
osteogenesis. Hence, the aim of the present study was to determine the potential role 
of IL-17A in osteogenic differentiation and regulation of OPG/RANKL system of the 
stem cells extracted from human exfoliated deciduous teeth (SHED). SHED were 
cultured in 2 different conditions; one in complete alpha minimum essential medium 
(-MEM) and the other in complete -MEM medium supplemented with osteogenic 
medium (OM). Both groups were treated with various concentrations of rIL-17A i.e. 
5, 10, 25, 50 and 100ng/ml respectively. Treated cells were then analyzed for 
proliferative activity by MTS assay, differentiation by alkaline phosphatase assay, 
mineralization activity by Alizarin red and Von Kossa stainings, expressions of bone 
and stem cell markers and apoptosis by flow cytometry analysis. Osteogenic 
differentiation potential of SHED was further evaluated by measuring the 
expressions of selected osteogenic markers i.e. ALP, COL1A1, RUNX2, OCN, OPN, 
OPG and RANKL by quantitative PCR and Western blot. The involvement of MAP 
kinase (MAPK) signalling pathway and miRNA-145 in the osteogenic differentiation 
mechanism of rIL-17A-treated SHED were also evaluated in the study. Treatment of 
rIL-17A on SHED and SHED + OM demonstrated increased proliferation and ALP 
activities in a dose-dependent manner. Similarly, stainings by Alizarin red and Von 
 xxiii 
 
Kossa indicated increased mineralization activity by rIL-17A-treated SHED and 
SHED + OM. Interestingly, treatments of cells with rIL-17A showed gradual 
declining of stem cells markers (c-Myc and Nanog) in both groups while increased 
expression of osteogenic markers (ALP and COL1A1) was evident as the days 
progressed. SHED-treated with rIL-17A also inhibited apoptosis in both groups. 
Moreover, the expressions of ALP, COL1A1, RUNX2, OCN, OPN and OPG were 
significantly up-regulated in rIL-17A-treated SHED in both groups. However, the 
RANKL expression was downregulated. Interestingly, the OPG/RANKL ratio was 
significantly enhanced in rIL-17A-treated groups. We also demonstrated that IL-17A 
activated MAPK signalling pathway by significant upregulation of all upstream 
activators and downstream targets of ERK, p38 and JNK pathway. In addition, rIL-
17A-SHED also showed increased expression of miR-145. These findings 
demonstrated for the first time that IL-17A promotes proliferation, enhances 
osteogenesis by promoting osteogenic differentiation through the alteration of 
OPG/RANKL signalling pathway and increases mineralization activity.  We also 
demonstrated possible roles of MAPK signalling pathway and miR-145 in osteogenic 
differerentiation of SHED induced by IL-17A. These findings suggest the pivotal 
role played by IL-17A in bone remodelling mechanism. 
 
1 
 
CHAPTER ONE 
INTRODUCTION 
1.1 Background of the study 
Bone serves as the basic foundation of the body and performs various functions such 
as providing fortification for internal organs, supporting muscles, producing red and 
white blood cells apart from acting as a warehouse for minerals (Kanczler et al., 
2008). Therefore, this construct is designed such that it constantly undergoes 
“remodelling” mechanism to sustain its original strength and structural integrity. It is 
regulated by two opposing forces, namely osteoblast activity (bone formation) and 
osteoclast activity (bone resorption) (Mulari et al., 2004). Osteoblasts influence the 
initiation and mineralization of bone at early stage of development followed by bone 
remodelling. Osteoblasts also modulate osteoclast differentiation and resorption 
(Neve et al., 2011). Osteoclasts are large, multinucleated cells that are specifically 
adapted to remove mineralized bone matrix.  
 
Receptor activator of nuclear factor-B ligand (RANKL) and osteoprotegerin (OPG) 
are the two regulatory factors in the metabolism of bone architecture (Alkady et al., 
2011). The discovery of the RANKL/RANK (receptor activator of nuclear factor 
kappa-β)/OPG system and its role in the regulation of bone resorption helped in 
identifying factors that regulate cell function. In normal bone remodelling and 
diverse pathologic conditions, RANKL/RANK signalling controls the formation of 
multinucleated osteoclasts from their precursors as well as their activation and 
survival (Kawashima et al., 2007). On the other hand, the OPG protects the skeleton 
from excessive bone resorption by binding to RANKL and inhibiting it from binding 
to its receptor, RANK (Saidak and Marie, 2012). Thus, RANKL/OPG system 
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appears to be vital for controlling the bone remodelling process and is an important 
determinant of bone mass and skeletal integrity (Whyte et al., 2013). 
 
Stem cells are undifferentiated cells which have the potential to differentiate into 
specialized cells. Although, bone marrow-derived mesenchymal stem cells 
(BMMSCs) which have good osteogenic differentiation potential are a source of seed 
cells, procuring BMMSCs involve excessive trauma and high expense (Li et al., 
2011). Dental stem cells are an easily available source of stem cells which have the 
capability for self-renewal and the capacity to differentiate into multiple lineages 
(Sedgley and Botero, 2012). Dental stem cells can be isolated from several soft 
tissues of the tooth located at different parts of the mouth. These include stem cells 
from pulp tissue which were isolated from permanent tooth (Gronthos et al., 2000) 
and stem cells isolated from human exfoliated deciduous teeth (SHED) (Miura et al., 
2003). Dental pulp stem cells (DPSCs) have the capability to differentiate into 
osteoblasts and form bone-like tissues, and further are devoid of the various 
disadvantages associated with BMMSCs, thus making it the most suitable option for 
bone regeneration. 
 
SHED stand leaps ahead of both DPSCs and BMMSCs, in their faster rate of 
proliferation, higher cell population doublings, easy access, absence of tissue 
destruction at donor site, lesser pain, multi-lineage differentiation and capacity for 
self-renewal (Jo et al., 2007). SHED also demonstrated osteoinductive capacity in 
vivo, which was absent in DPSCs. SHED also readily form bone/dentin in single 
colony‑derived SHED clones when injected to immunodeficient mice (Yamada et 
al., 2010). Exfoliated deciduous tooth is identical in some aspects to an umbilical 
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cord containing stem cells, thus offering an alternate but unique stem-cell resource 
for various potential clinical applications. 
  
A feature common to both SHED and BMMSCs was their osteogenic differentiation 
capacity (Yamaza et al., 2010). A previous study demonstrated that SHED 
transplanted in vivo, became an ideal source for osteoblasts and mineralized tissues 
to form bone (Laino et al., 2006). The repairing capability of SHED was displayed in 
a study by Seo et al. (2008) wherein the calvarial defects in mice were replaced with 
substantial bone formation. 
 
The interleukin-17 (IL-17) cytokine family is a group of proinflammatory cytokines 
consisting six members: IL-17A to IL-17F (Kolls and Linden, 2004; Kawaguchi et 
al., 2004). Cluster of differentiation (CD) 4+ memory T cells, CD8+ memory T cells, 
neutrophils, and eosinophils are the major cellular sources of IL-17 cytokines 
(Ferretti et al., 2003). Added to this, Th17 cells have also been recently identified as 
a novel subset of CD4+ effector T cells that produce IL-17A and IL-17F (Langrish et 
al., 2005).  
 
IL-17 group of cytokines perform various functions. IL-17A and IL-17F manage 
tissue inflammation by triggering the release of other proinflammatory cytokines and 
inducing neutrophil chemotaxis (Kolls and Linden, 2004). Moreover, IL-17 has been 
associated with different human ailments such as systemic lupus erythematosus, 
asthma, rheumatoid arthritis (RA), and allograft rejection (Langrish et al., 2005). The 
high levels of IL-17 serves as an indicator of the disease in RA patients (Kawashima 
et al., 2007).   
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A study by Huang et al. (2009) revealed the role of IL-17A in the bone 
microenvironment. Apart from stimulating the proliferation of human BMMSCs 
(hBMMSCs), IL-17 also induced the expression of macrophage colony-stimulating 
factor (M-CSF) and RANKL on human mesenchymal stem cells (hMSCs), thereby 
stimulating osteoclastogenesis, both in vitro co-culture and in vivo implant 
experiments. According to Ma et al. (2015), IL-17 hindered the mineralized 
deposition induced by MSC-hBMMSC and MSC-SHED.  A study by Osta et al. 
(2014) proved that the complex interaction between IL-17A and tumor necrosis 
factor (TNF) - α can trigger osteogenic differentiation of hMSCs. Even though 
studies have upheld the role of IL-17 in the regulation of the hMSC function towards 
the maintenance of bone homeostasis, the other functional roles of IL-17A on bone 
regulation, including RANKL/RANK/OPG system, still remains to be thoroughly 
explored.  
 
1.2 Statement of the problem 
Numerous studies have confirmed the favourable biological functions of IL-17A and 
its ability to induce hard tissue formation. The use of IL-17A in osteogenic 
differentiation of SHED and its clinical application has not been discussed 
elsewhere. In addition, the overall mechanism of RANKL/RANK/OPG in osteogenic 
differentiation of SHED induced by IL-17A has not been studied so far. The aim of 
the present study is to understand the role of IL-17A in modulating the 
RANKL/RANK/OPG system of SHED cultured in two different conditions. This 
study will lead to a better understanding of the roles of IL-17A in the mechanism of 
bone remodelling, and perhaps will pave the way for future development of a more 
5 
 
conducive environment for bone tissue engineering as well as provide related 
information regarding pathogenesis of bone diseases. 
 
1.3 Justification of study 
Bone remodelling is a continuous process of bone resorption and formation for the 
purpose of maintaining normal bone mass. Remodelling is a complex, tightly 
regulated process carried out by two key cell types: osteoclasts and osteoblasts. An 
imbalance in the bone remodelling process, favouring either osteoclast or osteoblast 
activity, leads to a number of clinical disease conditions eg: osteoporosis and RA. 
However, the exact mechanisms responsible for normal bone remodelling are still 
largely unclear.  
 
The role of IL-17A in MSCs has been studied. The study states that IL-17A 
stimulates the proliferation and differentiation of hMSCs and enhances bone 
remodelling by regulating massive bone turn over. But the role of IL-17A in bone 
remodelling of SHED have not been studied so far.  
 
In addition, bone regenerative medicine is currently a treatment modality that is 
continuously developed. SHED were reported to have similarity in their osteogenic 
differentiation capacity with BMMSCs, thereby indicating its potential of becoming 
a future bone regenerative agent. Therefore, understanding the cellular and molecular 
mechanisms involving SHED in bone remodelling will possibly provide important 
insights for therapeutic and tissue engineering developments.  
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1.4 Research objectives 
1.4.1 General objective: 
To elucidate the role of IL-17A in osteogenic differentiation of SHED cultured in 
two culture conditions. 
 
1.4.2 Specific objectives: 
1. To determine the effect of IL-17A on proliferation, differentiation and 
mineralization activities of SHED.  
2. To investigate the effect of IL-17A on cell death and apoptosis activities of 
SHED.   
3. To quantify the effect of IL-17A on osteogenic gene expression levels of SHED 
by quantitative PCR. 
4. To verify the effect of IL-17A on the mitogen - activated protein kinase (MAPK) 
signalling pathway in SHED using the RT² Profiler™ PCR Array.  
5. To quantify the effect of IL-17A on osteogenic proteins expression of SHED by 
Western blotting. 
6. To quantify the effect of IL-17A on miR-145 expression level of SHED by 
quantitative PCR. 
 
1.5 Research questions  
1. What is the effect of IL-17A on differentiation activity of SHED? 
2. What is the effect of IL-17A on mineralization activity of SHED? 
3. What are the effects of IL-17A on cell death and apoptosis activities of SHED? 
4. What are the roles of IL-17A on osteogenic markers expression of SHED? 
5. Does IL-17A modulate RANKL-RANK-OPG in SHED? 
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6. Does IL-17A promote bone remodelling mechanism in SHED? 
 
1.6 Research hypothesis  
IL-17A promotes osteogenic differentiation by modulating RANK/RANKL/OPG 
system of SHED cultured in two culture conditions. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 Bone 
Bones are the building blocks of the skeletal framework, which further acts as the 
basic structure on which the human body is constructed. Apart from providing 
structural integrity and thus regulating bodily movement, bone acts as a storage 
house for minerals and fats like triglycerides. It plays a key role in mineral 
hemostasis (calcium and phosphorus). The internal organs find a protective barrier in 
the skeletal framework. Bone also participates in the endocrine regulation of energy 
metabolism. Production of blood cells (haematopoiesis) is done by bone marrow, 
which is an integral part of the bones (Peel, 2009). Thus, bones are a boon to 
humans in multiple ways.  
 
The major activities associated with bones, apart from longitudinal and radial 
growth, are modelling and remodelling. The primary mechanism of bone growth, 
both longitudinal and radial, which mostly occurs during childhood and adolescence 
(Clarke, 2008), is followed by mineralization resulting in new bone formation. Bone 
modelling occurs in response to physiological or mechanical forces, like damages 
and aging, leading to overall changes in the shape and structure of bones (Peel, 2009; 
Crockett et al., 2011). Bone is constructed in such a manner that it is constantly 
subjected to “remodelling” mechanism. This is definitely to preserve its structural 
integrity and strength. Osteoblasts and osteoclasts, the two contrasting forces, 
regulate remodelling in the bone microenvironment (Mulari et al., 2004). Osteoblasts 
apart from being key regulators in osteoclast differentiation and resorption, also play 
9 
 
a prominent role in the initiation, early stage bone mineralization and bone 
remodelling (Neve et al., 2011).  
 
2.2 Bone remodelling 
Remodelling is a major bone regulatory mechanism, which occurs mostly during 
adulthood. The bone homeostasis is maintained by two processes namely bone 
formation and resorption. In detail, bone remodelling involves basically the 
breaking down of the old bones followed by deposition of the inorganic matrix 
and further apposition of the proteinaceous matrix (Peel, 2009). This continuous 
mechanism, mainly focused on cortical and trabecular sites, controls cellular 
activity through the life-span of the bone (Ralston, 2005; Kazama et al., 2010; 
Crockett et al., 2011; Sims and Martin, 2014). Bone remodelling revolves around 
two fundamental cells, namely, osteoblasts which are induced by mesenchymal 
cells and osteoclasts, induced by hemopoietic stem cells (HSCs). They are closely 
interconnected by regulatory proteins which help in the formation of new bone 
and the resorption of old bone (Rucci, 2008; Shahnazari et al., 2013).  
 
According to Bellido et al. (2014), bone remodelling is the balance of resorption 
and formation. In the remodelling mechanism, the coupling process of osteoblasts 
and osteoclasts occurs at definite sites, called basic multicellular units (BMU). 
The BMU in cortical and trabecular bone differs morphologically, although the 
mechanism is the same. The larger surface area of the trabecular bone helps in 
prompt remodelling than the cortical bone (Hadjidakis and Androulakis, 2006). 
The precursors of remodelling are supplied and distributed by bone marrow and 
bloodstream (Sims and Martin, 2014). Osteoprogenitor synthesizes osteoblasts 
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which further makes up the lining cells, of which some are stored as osteocytes 
(Downey and Siegel, 2006). The active osteoclast is characterized by its ruffled 
border with deep plasma membrane folds where the active bone resorption takes 
place (Andrades et al., 2013). The different phases in bone remodelling are as 
shown in Figure 2.1. 
 
2.2.1 Osteoblasts: formation and function  
The cuboidal osteoblasts, originating from osteoprogenitor MSCs, are the key 
players in bone formation (Caetano-Lopes et al., 2007). The process of 
osteoblastogenesis from mesenchymal progenitors to a mature bone forming cell 
involves 3 stages. First stage is commenced by the upregulation of chondrocyte 
master transcription factor sex-determining region Y (SRY)-box 9 (SOX9) in the 
mesenchymal progenitors (Akiyama et al., 2005). Thereafter, the osteoblast master 
transcription factor runt-related transcription factor 2 (RUNX2) transforms the 
proliferating precursor cells to the osteoblast lineage resulting in the formation of 
osteochondroprogenitors. Subsequently SOX9 is downregulated and thereby leads 
to the formation of RUNX2-positive osteoprogenitors (Robling et al., 2006). At 
this stage, Osterix (OSX), a second osteoblast master transcription factor mediates 
the expression of collagen type 1 (COL1) and alkaline phosphatase (ALP) (Nishio 
et al., 2006). This leads to the formation of preosteoblasts also known as immature 
osteoblasts. Additionally, the transcription factor activating transcription factor -4 
(ATF-4) also plays a key role in osteoblast differentiation. Hence, besides the 
transcription factors, certain genes are essential for the activation of pre-osteoblast 
proliferation (eg: c-Fos, c-Jun and c-Myc) and cell cycle progression (eg: histones 
and cyclines) are expressed along with the genes of the growth factors such as  
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Figure 2.1: Phases of bone remodelling (adapted from Siddiqui and Partridge, 2016). 
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fibroblast growth factor (FGF), insulin-like growth factor 1 (IGF-1), transforming 
growth factor (TGF), bone morphogenetic protein (BMP), cell adhesion proteins 
and COL1 (Feldman, 2013). The second stage starts with the maturation and 
organization of the bone extracellular matrix (ECM) following the proliferatory 
phase. This stage is characterized by the continuation of collagen synthesis and 
cross-link maturation. Gene responsible for this phase is ALP (Feldman, 2013). 
Under alkaline conditions, the crucial role of ALP in bone calcification is 
characterized by hydrolysis of ester bonds in organic phosphate compounds. This 
suggests that high ALP activity corresponds to ECM formation before moving to 
the mineralization phase (Zhu et al., 2010; Costa-Pinto et al., 2011). 
 
The third stage is characterized by the downregulation of the genes that aid in 
proliferation as well as upregulation of genes involved in mineralization phase. 
During mineralization phase, maximal expression of genes encoding the non-
collagenous proteins such as osteocalcin (OCN), osteopontin (OPN) and bone 
sialoprotein (BSP) occurs (Feldman, 2013).  In the final phase, collagenases are 
elevated and 50-70% of osteoblasts undergo apoptotic activity (Clarke, 2008; 
Feldman, 2013). 
 
Osteoblasts regulate the development, maintenance and repair of bone thereby 
regulating the bone remodelling process (Tanaka et al., 2005). The other functions 
performed by osteoblasts are osteoclast differentiation and expansion of HSCs. 
The bone formation is characterized by the synthesis of ECM proteins such as 
COL1, OCN, OPN and BSP on which osteoid is deposited (Neve et al., 2011; Kini 
and Nandeesh, 2012). Osteoblasts generate increasing levels of bone specific ALP 
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mainly on the outer membrane, which catalyzes mineralization (Golub and 
Boesze-Battaglia, 2007). Osteoblasts secrete these proteins into the blood which 
act as signals for bone formation (Harimoto et al., 2012).  
 
Apart from regulating the flow of calcium to and from the bone, the osteoblast 
cells which form the ECM of bone, act as a warehouse for a variety of growth 
factors. Also, to be noted is the structural integrity and strength provided by these 
cells to the bone (Long, 2012). They also signal peculiar proteins which induces 
the osteoclasts (Calabrese et al., 2012). Moreover, the non-collagenous proteins 
and COL1 secreted by the osteoblasts control bone mineralization (Andrades et 
al., 2013). The major functions of osteoblast are pictorially depicted in Figure 2.2.  
 
2.2.2 Osteoclasts: formation and function 
Osteoclasts are large multi-nucleated cells formed by the fusion of the precursors 
of the monocyte macrophage lineage originated from hematopoietic cells (Crockett 
et al., 2011). RANKL plays a pivotal role in osteoclast formation whereas M-CSF 
is essential for the proliferation, survival and differentiation of osteoclast 
precursors (Boyce and Xing, 2008). Medical science suggests that most of the 
bone ailments in humans are characterised by a process known as bone resorption. 
An inflammation always transmogrifies resorption of bone usually through three 
important processes. Primarily, the pro-inflammatory cytokines modulate the 
osteoclast function by means of RANK and its functional ligand (RANKL) also 
known as TNF related activation induced cytokine (TRANCE). 
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Figure 2.2: Functions of osteoblasts. Abbreviation: HSC; Haemopoetic Stem Cells 
(Adapted from Calabrese et al., 2012; Harimoto et al., 2012; Long, 2012). 
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Secondly, it happens through the crucial role of M-CSF and, thirdly, through 
transcription factor, PU.1. M-CSF passes its osteoclastogenic signals to the cell 
through the stimulating factor receptor, c-fms. They further stimulate the 
expression of RANK in monocyte-macrophage precursor cells. The transcription 
factor PU.1 actually regulates the development of osteoclasts by controlling the 
expression of c-fms (Raggat and Patridige, 2010). The major pathways of 
osteoclast differentiation are pictorially depicted in Figure 2.3.  
 
In one of these pathways, the RANKL/RANK signalling cascade induces 
osteoclastogenesis, which is commenced by the activation of TNF receptor-
associated factor 6 (TRAF6), described by the pioneers Armstrong et al. (2002). 
The two most common downstream mediators in this pathway are nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF- κB) and activated protein 
1(AP-1). Several co-stimulatory molecules are present in the other pathway such 
as osteoclast associated receptor (OSCAR), paired immunoglobulin-like receptor 
A (PIR-A), signal-regulatory protein β (SIRPβ) and triggering receptor expressed 
on myeloid cells (TREM2) which are essential for osteoclast activation. They 
initiate calcium ions (Ca2+) signalling cascade through immunoreceptor tyrosine-
based activation motifs (ITAM) phosphorylation. The Ca2+ signalling cascade 
along with the action of transcription factors such as NF-κB and c-fos result in the 
auto amplification of nuclear factor of activated T cells cytoplasmic1 (NFATc1), 
which is the master regulator of osteoclastogenesis (Koga et al., 2004; Aliprantis 
et al., 2008). 
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Figure 2.3: Major pathways of osteoclast differentiation. Footnotes: RANKL, 
Receptor activator of nuclear factor-κB ligand; RANK, receptor activator of 
nuclear factor kappa-β; TRAF6, TNF receptor-associated factor 6; NFκB, 
nuclear factor kappa-light-chain-enhancer of activated B cells; NFATc1, nuclear 
factor of activated T cells cytoplasmic1; TREM2, triggering receptor expressed 
on myeloid cells; SIRPβ, signal-regulatory protein β; PIR-A, paired Ig-like 
receptor A, OSCAR, osteoclast associated receptor; ITAM, immunoreceptor 
tyrosine-based activation motif (Adapted from Yamashita et al., 2012) 
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Activated osteoclasts generate an acidic microenvironment in the active bone 
resorption site via secretion of hydrogen ions that dissolve the bone minerals. 
Additionally, several proteases and hydrolases degrade the organic matrix 
resulting in the destruction of its main constituent, COL1 (Novack and 
Teitelbaum, 2008). 
 
2.2.3 Osteocytes: formation and function 
Osteocytes constitute 95% of all bone cells. These cells are terminally differentiated 
osteoblasts formed when osteoblasts get implanted in the matrix. Prompt spurts of 
bone calcium across filipodial gap junctions accelerate communication between 
osteoblasts on the bone surface and osteocytes inside the bone (Dallas and 
Bonewald, 2010; Plotkin, 2011). During its implantation in the bone matrix, 
osteoblasts totally change their morphology into a stellar shape with 50 or more thin 
extensions known as osteocyte processes. During this transformation the osteoblast 
cells lose over 70% of cell organelles and cytoplasm (Rochefort et al., 2010). The 
resulting osteocyte network provides microporosity in the mineralised bone. 
Osteocyte bodies are contained within spaces referred to as lacunae, whereas their 
connected processes are contained within channels (termed canaliculi) – together 
they make up the lacunar–canalicular network.  
 
Osteocytes surveil mechanical stress (i.e. pressures or cracks) in the bone and further 
generate prostaglandins. Thus, they are mechanosensory cells belonging to the 
osteoblastic family that play a pivotal role in the regulation and adaptation of bone 
(Calabrese et al., 2012; Link, 2013). They initiate osteoclasts into dissolving the 
bone (Xia et al., 2010).  But it is now evident that they also sense metabolic signals. 
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(Manolagas and Parfitt, 2010).  The osteocytes positively regulate osteoblasts 
through the production of messengers, such as nitric oxide and prostaglandin E2, and 
they also negatively regulate osteoblasts through secretion of sclerostin (Rochefort et 
al., 2010).  
 
2.2.4 RANK/RANKL/OPG signalling 
A close study of bone metabolism reveals the involvement of OPG and RANKL in 
balancing the whole metabolism (Alkady et al., 2011). The discovery of 
RANKL/RANK - OPG system can be considered as a quantum leap in the 
understanding of bone biology. It was first identified in the 1990s. In 1997, 
Simonet et al. discovered OPG as an inhibitor of osteoclastogenesis. It was 
followed by the discovery of RANKL in 1998 as an inducer of osteoclastogenesis. 
The interruption in this system is responsible for a disrupted bone homeostasis. 
The newly found cytokine RANKL is the corner stone in the osteoclast generation 
and its activity. RANKL, RANK and OPG are pivotal regulators of bone 
metabolism belonging to TNF receptor and ligand families. RANKL, a type 2 
ligand protein of TNF ligand family is an essential activator for osteoclast 
differentiation. This factor exists as a homotrimeric protein and is expressed as a 
membrane - bound protein on the surface of osteoblasts, osteocytes, marrow 
stromal cells, activated T cells, and B-cells. M-CSF, along with most osteotropic 
factors such as IL-1, IL-11, prostaglandin E2 and 1,25-(OH)2D3, induces 
osteoclast formation by binding to marrow stromal cells, which in turn express 
increased levels of soluble or membrane forms of RANKL (Herman et al., 2008).  
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RANK is a heterotrimeric transmembrane protein member of the TNF receptor 
superfamily that appears to be expressed in osteoclast precursors, mature 
osteoclasts, dendritic cells, mammary glands and some cancer cells, like breast 
and prostate cancers. RANKL binds to its receptor RANK, expressed by 
hematopoietic cells and thereby initiates osteoclast development. This action is 
indispensable for osteoclast differentiation, function and survival (Kawashima et 
al., 2007; Papadopouli et al., 2008; Trouvin and Goeb, 2010). 
  
OPG which is a secreted member of TNF receptor family, is produced similar to 
RANKL molecule, by osteoblasts and marrow stromal cells. Its main action is to 
inhibit osteoclast formation and activity. OPG, the name itself signifies protector 
of bone. It is the first molecule of the three different key players that can control 
osteoclast function. Also known as osteoclastogenesis inhibitor factor, it is a 
soluble protein secreted by osteoblasts, 64% of which is produced by B-cells. 
OPG production is controlled by cytokines, growth factors, hormones and 
Wingless protein (Wnt)/beta-catenin. OPG acts as a soluble inhibitor of osteoclast 
maturation and osteoclast activation in vitro and in vivo. In the RANKL-RANK-
OPG mechanism, OPG binds with RANKL hindering further interaction of 
RANKL with RANK. This process inhibits the differentiation of preosteoclasts 
into mature osteoclasts (Figure 2.4) (Saidak and Marie, 2012). Thus, RANKL and 
OPG appear to be the major determinants in the control of the bone remodelling 
process (Whyte, 2013). 
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Figure 2.4: RANKL-RANK-OPG mechanism (Adapted from Lee, 2010) 
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OPG-RANKL system acts as a platform to delve into the intricacies of bone 
remodelling mechanism (Boyce and Xing, 2008). In metabolic bone diseases, 
variations in the OPG-RANKL system has resulted in severe complications 
(Hofbauer et al., 2004). Studies have indicated that excessive production of 
RANKL being inhibited by the high levels of OPG have accelerated bone metastasis 
in vivo (Haynes et al., 2003). OPG/RANKL ratio is a major determinant regarding 
the performance of adipocyte-secreted factors towards bone formation (Kuhn et 
al., 2012). Another study have dealt with the effectiveness of RANK/RANKL/OPG 
system towards measuring the oxidative and anti-oxidative properties of metals in 
bone activity (Brzoska and Rogalska, 2013).  
 
It has been stated that deviations in the RANK/RANKL/OPG network can result 
in bone diseases such as RA, cancerous bone metastases (osteolytic metastases) and 
osteoporosis (Terpos et al., 2005; Wada et al., 2006). Studies have also dealt with 
the effectiveness of OPG/RANK/RANKL marker levels as an indicator of the 
presence of bone metastases in breast cancer (Ibrahim et al., 2011). It can be 
inferred that OPG/RANKL/RANK modulation holds a pivotal role towards 
understanding bone regulation and inhibiting bone diseases (Boyce and Xing, 2008).  
 
2.3 Necessity of bone substitute 
Bone substitutes are essential for healing traumatic bone injury through orthopaedic, 
craniofacial, and dental reconstructions. Bone is the second most commonly 
transplanted tissue (Shegarfi and Reikeras, 2009)). It is estimated that greater than 
200 million people are affected with osteoporosis (WHO, 2015). A report published 
on National Osteoporosis Foundation website accessed on August 2, 2016 stated the 
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following facts regarding osteoporosis patients in US. Osteoporosis was the major 
cause for the approximately 1.5 million fractures occurring annually in the US. 
Majority of the 10 million Americans suffering from osteoporosis were at immediate 
risk of hip, spine (vertebra) or wrist (distal radius) fractures. Further, osteoporosis 
related fractures are presumed to follow an increasing pattern for the upcoming 60 
years. In a survey conducted in 27 countries of the European Union (EU27), 22 
million women and 5.5 million men were suffering from osteoporosis. Among these 
patients, 610,000 suffered from hip fractures, 520,000 from vertebral fractures, 
560,000 from forearm fractures, and 1,800,000 from other fractures like fractures of 
the pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum, and other femoral 
fractures, totalling 3.5 million new fractures (Hernlund et al., 2013). For this ailment 
having a low cure rate of 10-15%, one of the most effective treatment modalities is 
bone graft substitutes (Larsson and Procter, 2011)). Annual global estimates of 
patients undergoing this treatment modality are approximately 2.2 million 
(International Osteoporosis Foundation, 2009).  
 
Major treatment modalities for bone tissue loss are autografts, allografts, 
implantation of substitute materials and more recently, application of recombinant 
BMPs. Certain limitations are associated with these procedures. Autograft, a mostly 
redundant procedure, was hindered by the difficulty in procuring healthy tissue, high 
chance of donor site morbidity, and pain associated with the harvest (Chou et al., 
2007). Allografts are limited by the decreased biological and mechanical properties 
after the procedure, high possibility of disease transmission and hostile 
immunological host response (Reikeras et al., 2008), leading to a high rate of failure 
(Reichert et al., 2011). Synthetic materials which account for approximately 10% of 
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bone substitutes  suffer from various limitations, namely, absence of osteogenic or 
osteoinductive component, toxicity, wear, biodegradability, acute inflammations in 
the host and  chances of rejection due to insufficient biomechanical compatibility 
(Bueno and Glowacki, 2009). 
 
Due to these drawbacks associated with bone substitutes, there exists an exigent need 
for substitutes which are osteoinductive, osteogenic, osteoconductive, 
angioinductive, permit growth of blood vessels, degrade within a certain time period 
and possess biomechanical stability. 
 
2.4 Tissue engineering 
Tissue engineering comes as a possible alternative by developing biological 
substitutes which can restore, preserve or ameliorate tissue function (Holzapfel et al., 
2012; Jakob et al., 2012). The multitude of approaches to bone tissue engineering 
involve either or all of the following vital components: harvested cells, scaffolding 
matrix and regulatory/inductive/stimulatory signals to direct osteoblastic 
differentiation (Bose et al., 2012; Frey et al., 2012; Yun et al; 2012). 
 
2.4.1 Cells for bone tissue engineering 
The ideal cell for cell-based tissue engineering should be effortless to acquire and 
expand, non-immunogenic, genetically modifiable, ethically non-controversial and 
possesses the capacity to differentiate to the osteogenic lineage. Majority of the cells 
which are presently studied for bone tissue engineering are multipotent MSCs 
(Bianco et al., 2008). According to Hutton and Grayson, (2014), MSCs are a 
category of bone marrow cells which possess the capacity to differentiate to bone.  
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These were also termed as colony-forming unit-fibroblast (CFU-F) because of their 
ability to form colonies when plated at low density (Bianco et al., 2013).  In 1991, 
Caplan had coined the term, MSCs and highlighted their capability to differentiate to 
all cells of the mesodermal lineage (Caplan, 1994). 
 
Various sources of MSCs have been discovered for the clinical applications over the 
years (Annibali et al., 2014) such as umbilical cord blood (Erices et al., 2000), dental 
pulp (Gronthos et al., 2000), SHED (Miura et al., 2003), synovial membrane (De 
Bari et al., 2001), adipose tissue (Zuk et al., 2002), placenta (In’t Anker et al., 2004), 
Wharton’s jelly (Wang et al., 2004), scalp tissue (Shih et al., 2005), umbilical cord 
perivascular cells (Sarugaser et al., 2005), skeletal muscle perivascular cells (Crisan 
et al, 2008), amniotic fluid (Nadri and Soleimani, 2007), and breastmilk (Patki et al., 
2010). 
  
2.4.1(a) Bone marrow stromal cells (BMSCs)  
The most commonly used MSCs in bone tissue engineering are BMSCs. Even 
though BMSCs have cured different bone defects (Neman et al., 2012; Geng et al., 
2013), the extraction of bone marrow is difficult and the yield of CFU-F is low, 
approximately 1:10,000 at birth diminishing to 1:250,000 in adult marrow (Caplan, 
2009). Moreover, the osteogenic capacity of the cells is inversely proportional to the 
age of the donor (Mueller and Glowacki, 2001). Although BMMSCs were used as 
the main cell source for bone tissue engineering (Phinney and Prockop, 2007) and 
showed favourable results when used instead of autogenous bone grafting in clinical 
trials (Yamada et al., 2004; Yamada et al., 2008). The BMMSCs are not used 
frequently nowadays because of its disadvantages such as invasive harvest of cells, 
